Case Studies

Pharma Intelligence Consulting - Case Studies

Best-in-class data sets & primary research to address your business needs.

Probability of Technical Success

Probability of Technical Success

A large biotech needed the correct analogs for follow-on biologics PTS in Oncology and Respiratory programs across a range of segments to assess the risk of their portfolio.

Find out more

Commercial Optimization

Commercial Optimization

Our client asked us to help support their CNS product portfolio strategy by helping to understand the clinical and commercial potential of the schizophrenia market.

Find out more

Qualitative market research with payers in the EU and Japan

Qualitative market research with payers in the EU and Japan

The client was looking to develop a deeper understanding of the payer landscape in Europe and Japan as part of an overall market opportunity assessment

Find out more

Benchmarking loss of exclusivity (LOE) and price evolution

Benchmarking loss of exclusivity (LOE) and price evolution

Our client wished to understand the potential impact of the competitor’s drug going generic on their brand.

Find out more

Commercial assessment and forecast of IV anti-infective

Commercial assessment and forecast of IV anti-infective

Our client was considering in-licensing an IV formulation of an anti-infective.

Find out more

Probability of Technical Success

PROBLEM

A large biotech needed the correct analogs for follow-on biologics PTS in Oncology and Respiratory programs across a range of segments to assess the risk of their portfolio

SOLUTION

  • Our Consultants developed rules for defining each of the relevant segments including:
    – “First-in-class” and “follow-on”
    – “Lead” and “Supplemental” indications
    – “Big Pharma” and “Biotech”
  • We then conducted detailed analysis of thousands of lines of data and classified each program/indication combination for each of the relevant segments
  • Referencing the assigned classifications, we used BioMedTracker’s Probability of Success Calculator to determine the average likelihood of approval for all relevant programs in Oncology and Respiratory therapy areas

OUTCOME

The client was able to use the custom segmentation of data to risk-adjust the forecasts for several of their portfolio assets with probability of success percentages that were most suited to those assets
Free Demonstration


Commercial Optimization

ISSUE
Our client asked us to help support their CNS product portfolio strategy by helping to understand the clinical and commercial potential of the schizophrenia market

APPROACH

  • Our team evaluated the market opportunity by:
  • Mapping clinical pathways and patient segments
  • Providing a detailed characterization of the current competitive landscape
  • Mapping high probability/high impact future market trends
  • Modeling the implications of market events on the overall market, as well as our client’s product portfolio
  • Assessing pricing and reimbursement potential
  • We worked with our client to design a comprehensive research program that included:
  • 26 KOL interviews and survey completed by 252 treating psychiatrists distributed across the US, EU, and Japan

OUTCOME
Our Consultants delivered a comprehensive overview of the market, products and stakeholders, along with a product attribute analysis, product forecast, and pricing & reimbursement potential for the US, EU, and JP
Free Demonstration


Qualitative market research with payers in the EU and Japan

ISSUE
Our client was developing a product for the treatment of Tardive Dyskinesia (TD) and Tourette’s Syndrome (TS). The client was looking to develop a deeper understanding of the payer landscape in Europe and Japan as part of an overall market opportunity assessment

APPROACH

  • We leveraged all proprietary and public data sources and collated existing data provided by the client
  • We conducted primary market research with treating physicians and payers (n=30) in the form of TDIs lasting 45-min

OUTCOMES

  • The output of this project entailed a comprehensive disease assessment which provided our client with actionable insights around patient dynamics, current and future disease management, unmet needs and competitive environment
  • The client used our analysis to inform pricing & reimbursement decisions for their project in the geographies of interest
  • Our analysis further informed the client’s positioning strategies and decisions on how to differentiate their product against competitors

Free Demonstration


Benchmarking loss of exclusivity (LOE) and price evolution

ISSUE
A product was about to go generic within the metastatic renal cell carcinoma (mRCC) indication. Our client wished to understand the potential impact of the competitor’s drug going generic on their brand and whether there would be any spill-over effects

APPROACH

  • Pharma Intelligence Consulting selected a set of historical analog drugs to model past benchmarks
  • We adopted five analytical methods to selecting the right analogs: 1) Bivariate analysis 2) Time series progression 3) Unit price differential 4) Market share evolution and 5) Weighted mean prioritization

OUTCOMES

  • Our comprehensive market report identified the most appropriate analogs for this therapeutic area and helped the client quantify the relationship between price-volume, and better understand the impact that pricing strategies can have on demand post LOE. Our analysis further outlined the speed and extent to which generic penetration occurs and the spill- over effects on share across the category
  • Our market segmentation based on the risk of generic exposure enabled the client to effectively strategize across regions

Free Demonstration


Commercial assessment and forecast of IV anti-infective

ISSUE
Our client was considering in-licensing an IV formulation of an anti-infective. In order to understand the commercial opportunity for Product X, the client was interested in commissioning a consultancy to complete a comprehensive commercial opportunity assessment.

APPROACH
Mix of secondary research and primary market research with physicians, pharmacists, KOLs and patients (including a quantitative research study with N=50 physicians in the US)

OUTCOMES
Our comprehensive landscape of the US market and a robust forecast model was used by our client in potential partnerships and investor discussions.
Free Demonstration


Contact us for a free demonstration

Sorry, this form has been permanently removed.

Need assistance with this form?

Back to the top Back to the top
Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726